HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $47.00

Keros Therapeutics (NASDAQ:KROS) had its price objective reduced by research analysts at HC Wainwright from $100.00 to $47.00 in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 155.02% from the stock’s current price.

KROS has been the subject of a number of other research reports. Wells Fargo & Company increased their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research report on Wednesday. Wedbush reissued an “outperform” rating and set a $84.00 price objective on shares of Keros Therapeutics in a report on Thursday, November 7th. BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. Finally, William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.33.

Keros Therapeutics Trading Down 73.2 %

NASDAQ:KROS opened at $18.43 on Friday. The firm has a market capitalization of $746.60 million, a price-to-earnings ratio of -3.54 and a beta of 1.20. The firm’s fifty day simple moving average is $59.95 and its 200 day simple moving average is $52.83. Keros Therapeutics has a twelve month low of $15.67 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.33) earnings per share. On average, analysts predict that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV raised its holdings in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics in the third quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Keros Therapeutics in the second quarter valued at $128,000. Finally, LMR Partners LLP bought a new position in shares of Keros Therapeutics in the third quarter valued at $213,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.